AACR 2023: D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice

AACR 2023: D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice

Conclusions

• D02 is a fully human IgG1 antibody specific to IL2RA that was obtained from RenMab^TM humanized immunoglobulin mice.
• D02 binds both human and cynomolgus monkey IL2RA with high affinity.
• D02 binds to the sushi2 epitope of IL2RA without obstructing the binding of IL-2 or inhibiting IL-2 signaling.
• D02 exhibits anti-tumor efficacy when administered to mice harboring MC38 tumors.